Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: Brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug-Reference-Cited by-同舟云学术

Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: Brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug

Published:2011-04 Issue:4 Volume:46 Page:979-992
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Teixeira Cátia,Gomes José R.B.,Gomes Paula,Maurel François

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference139 articles.

1. First report of AIDS;MMWR Morb. Mortal. Wkly. Rep.,2001

2. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS);Barre-Sinoussi;Science,1983

3. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS;Gallo;Science,1984

4. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS;Levy;Science,1984

5. Human immunodeficiency viruses;Coffin;Science,1986

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunological and molecular assessment of HIV-1 mutations for antiretroviral drug resistance in Saudi Arabia;PLOS ONE;2024-06-26

2. A quantum mechanical investigation of nanocone oxide as a drug carrier for zidovudine: AIDS drug;Journal of Molecular Graphics and Modelling;2023-12

3. Natural products as potential lead compounds to develop new antiviral drugs over the past decade;European Journal of Medicinal Chemistry;2023-11

4. Peptide Triazole Thiol Irreversibly Inactivates Metastable HIV-1 Env by Accessing Conformational Triggers Intrinsic to Virus–Cell Entry;Microorganisms;2021-06-12

5. In vivo administration of anti-HIV hyper-immune eggs induces anti-anti-idiotypic antibodies against HIV gp120 peptides (fragments 308-331 and 421-438) and against HIV gp41 peptide (fragment 579-601) which have demonstrable protective capacity;2021-05-02